The Effect of Si-Doping on the Release of Antibiotic from Hydroxyapatite Coatings

Mirjam Lilja¹,², Carl Lindahl³,⁴, Wei Xia³,⁴, Håkan Engqvist³, Maria Strømme¹*

¹Division for Nanotechnology and Functional Materials, The Ångström Laboratory, Department of Engineering Sciences, Uppsala University, Uppsala, Sweden; ²Sandvik Coromant AB, Stockholm, Sweden; ³Division for Applied Material Science, The Ångström Laboratory, Department of Engineering Sciences, Uppsala University, Uppsala, Sweden; ⁴BIOMATCELL, VINN Excellence Center of Biomaterials and Cell Therapy, Gothenburg, Sweden.

Received April 23rd, 2013; revised June 1st, 2013; accepted June 12th, 2013

ABSTRACT

Herein, we show that incorporation of ions during biomimetic coating deposition may be utilized to tailor the drug loading capacity of hydroxyapatite (HA) coatings. Pure biomimetic HA (HA-B) and Si-doped equivalents (SiHA-B) where deposited by a biomimetic process onto titanium dioxide covered titanium substrates. The antibiotic Cephalothin was incorporated into the coatings by adsorptive loading and the release was studied in-vitro. SiHA-B coatings exhibited superior drug incorporation capacity compared to pure HA-B coatings, resulting in a drug release profile dominated by an initial 10 min burst effect while a more prolonged 10 hour release was observed from HA-B coatings. The results emphasize the possibility to impact the drug release kinetics from implant coatings by selective doping elements and the use of thin, biomimetic HA-coatings as drug delivery vehicles. Functionalizing metal implants with SiHA-B coatings presents an interesting strategy towards creating synergetic effects through ion- and antibiotic release and, hence, contributing both towards preventing post-surgical infections and at the same time enhancing the bone-bonding ability.

Keywords: Titanium Dioxide; Hydroxyapatite; Cephalothin; Drug Release; Si-Doping

1. Introduction

The use of bioactive hydroxyapatite (HA) coatings on metal implant surfaces have been reported to improve fixation in orthopaedic implants, especially during the early stage of healing [1,2]. To further enhance the bone-bonding ability at the bone/implant interface, anionic and cationic substitutions have been investigated to mirror the mineral component of the bone more accurately [3]. Studies have shown that HA coatings containing foreign ions can improve the cell proliferation and in-vivo bone tissue response [4-6]. Strontium (Sr) has been proven to increase bone strength and reduce bone resorption [7,8], whereas silicon (Si) has the ability to increase the bone mineralization rate and enhance the osteoblast proliferation [9], differentiation and collagen production [10,11]. Despite the promising properties of HA coatings in terms of early bone appositions and long-term fixation, the osseointegration process can be hampered by the presence of bacteria in the peri-implant bone healing area [12].

HA coatings deposited by biomimetic methods (HA-B) have been tested successfully as drug delivery vehicle for, e.g., bisphosphonates and antibiotics in order to promote bone formation around the implant site or reduce the risk of infections [12-19]. Biomimetic deposition is a coating method carried out at ambient temperature [20] and it allows for production of nanoporous, calcium-deficient HA-B coatings on titanium substrates [21,22]. Crystalline anatase and rutile phases of TiO₂ have shown superior bioactivity compared to native titanium oxide surfaces [23-26] and are, thus, suitable materials for implant surfaces.

Parameters, such as solubility, binding capacity and net charge of the drug have been shown to play an important role for the drug release from implant surfaces [27, 28]. Based on the promising in-vivo results of ion-doped HA-B coatings, the combined use of biologically active ions and antibiotics incorporated into HA-B presents an interesting path to follow. A dual release strategy is expected to stimulate and improve cell proliferation while at the same time delivering pharmaceutical agents to
combat and prevent implant related infections. Compared to pure HA, ion-doped HA has a different solubility, crystallinity and topography, which are expected to influence the bone response around the implant [29] as well as the drug release.

The aim of this study was to investigate the impact of Si-doping on the microstructure of biomimetically deposited HA coatings and to evaluate the effect on the drug loading and release properties of these in order to promote a beneficial, dual effect as described above.

2. Materials and Methods

2.1. Coating Deposition

Square substrates (20 × 20 mm) of commercially available titanium grade 4 were coated with an anatase phase dominated crystalline TiO₂ by cathodic arc evaporation during a deposition time of 20 min, as described elsewhere [30]. The TiO₂ coated substrates were placed, either perpendicular standing or horizontally laying (denoted as (p) or (h), respectively), into plastic tubes filled with 40 ml Dulbecco’s phosphate buffered saline (PBS) (Sigma) for 7 days at 60°C for deposition of a HA-B layer on the surfaces. SiHA-B coatings were obtained by immersing the TiO₂ coated samples into modified PBS (Si-PBS) with a silicate ion concentration of 2 mM, as described earlier [31].

The coated samples were subjected to a drug loading procedure following the HA-B and SiHA-B coating deposition where they were placed for 1 hour in 40 ml PBS containing 1 mg Cephalothin (Sigma) at 37°C.

2.2. Characterization

X-ray diffraction (XRD) measurements of the deposited SiHA-B and HA-B coatings were performed using a Siemens D5000 diffractometer operating with 1° grazing incidence angle in parallel beam geometry using CuKα radiation (wavelength λ of 1.540598 Å). A step size of 0.1° and a scan step time of 4s were used for the scans recorded between 20° and 34° 2θ. The morphology of the coatings was examined by a Zeiss 40 Scanning electron microscope (SEM). SEM images of SiHA-B and HA-B cross sections obtained by ion milling (E-3500, Hitachi) were recorded to evaluate the thicknesses and structures of the deposited coatings.

2.3. Antibiotic Release

The release of Cephalothin was analyzed with UV-vis absorption spectroscopy (UV-1650PC, Shimadzu) at a wavelength of 238 nm. During the release experiments 2 plates were placed in 10 ml deionized water that was circulated through the measuring cell using a peristaltic pump. The adsorption was automatically measured at time intervals of 5 min under the total measurement time of 16 h. The measurements were carried out in triplicates to confirm the reproducibility of the release kinetics. After the release measurements the coatings were dissolved in hydrochloric acid to confirm the absence of drugs remaining in the coatings.

3. Results and Discussion

The XRD patterns of TiO₂ coated substrates after being immersed for 7 days in PBS or Si-PBS are presented in Figure 1 and confirm the presence HA in both coating types. SEM images recorded on cross sections of the biomimetically deposited coatings show rather thin HA-B and SiHA-B coatings with an average thickness of only ~200 - 250 nm, Figures 2(a) and (c). In agreement with literature data [31] both coatings display a flake-like morphology, Figures 2(b) and (d). The images reveal a porous network of small crystals for both coating types. The pure HA-B coatings appear to have a slightly denser topography (Figure 2(c)) compared to SiHA-B coatings (Figure 2(d)), and the cross section images support this by displaying a denser network of crystals at the interface towards the underlying TiO₂ surface for HA-B coatings, Figure 2(a).

Figure 3 shows typical release curves in water from HA-B and SiHA-B coatings loaded with Cephalothin. The displayed curves represent the release of all drugs that were incorporated during the drug loading experiment; no residual drug could be detected in any of the coatings after 16 h of release.

A rapid release of the drug is observed within the first 10 min for all sample types, followed by a slower, prolonged release period continuing for about 10 hours. The total amount released from the SiHA-B coatings is larger than from the HA-B coatings deposited under compara-
The Effect of Si-Doping on the Release of Antibiotic from Hydroxyapatite Coatings

Figure 2. SEM images of cross-sections ((a) and (c)) and topography ((b) and (d)) of HA-B (left column) and SiHA-B coated TiO₂ surfaces (right column) after an immersion time of 7 days in perpendicular position (p) in PBS and Si-enriched PBS, respectively.

Figure 3. Initial release curves (lower panel) and release during the entire time period under study (upper panel) presenting the amount of Cephalothin released in room-tempered deionized water per surface area for SiHA-B and HA-B samples coated in the displayed positions (p or h). All samples were adsorptively loaded with Cephalothin for 1 h at 37°C.

The Use of Antibiotics with Positive Charge at Neutral pH, such as Tobramycin [39], could present one way to impact the affinity towards the negatively charged SiHA-B surface and hence a possibility to obtain drug release profiles offering both initial burst and sustained release. The total amounts of Cephalothin released from both
HA-B and SiHA-B are similar to amounts previously proven to be sufficient for inhibition of *S. aureus* and *S. epidermidis* [17] which are common causes of implant related infections.

4. Conclusion

We show that incorporation of ions during biomimetic coating deposition may be utilized to tailor the surface area and, thus, the drug loading capacity, of HA coatings. Incorporation of Si ions in HA resulted in a higher uptake and a faster release of Cephalothin as compared to pure HA. In agreement with earlier studies the measured amounts of Cephalothin released are sufficient to inhibit the growth of *S. aureus* and *S. epidermidis*. Functionalizing implant surfaces with biomimetically deposited HA coatings, which combine the release of both bioactive ions and antibiotics, present an interesting path to follow in the development of dual-activity implants contributing towards both bone tissue regeneration and minimizing implant related infections.

5. Acknowledgements

The Swedish Research Council, the Carl Trygger Foundation, the Göran Gustafsson Foundation, the Swedish Foundation for Strategic Research and Vinnova are acknowledged for financially supporting our research.

REFERENCES


